CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Institute of Hematology & Blood Diseases Hospital, China
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Kousai Bio Co., Ltd.
Nantes University Hospital
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Comenius University
Eilean Therapeutics
University of Manitoba
Centre Hospitalier Universitaire de Nice
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Pennsylvania
National Cancer Institute (NCI)
Washington University School of Medicine
National Cancer Institute (NCI)
The Royal Wolverhampton Hospitals NHS Trust
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
University of Miami
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
University of Turin, Italy
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Fred Hutchinson Cancer Center
Nurix Therapeutics, Inc.
Dana-Farber Cancer Institute
Arovella Therapeutics Ltd
St. Justine's Hospital
University of Arizona
Northside Hospital, Inc.
Beth Israel Deaconess Medical Center
M.D. Anderson Cancer Center
AstraZeneca
Assiut University
Mayo Clinic
First People's Hospital of Hangzhou
Second Affiliated Hospital, School of Medicine, Zhejiang University
Novartis
Sheba Medical Center
University Hospital, Angers
Institute of Hematology & Blood Diseases Hospital, China
Children's Oncology Group
Institute of Hematology & Blood Diseases Hospital, China
Eli Lilly and Company
Shenzhen TargetRx Co., Ltd.